Plasma apelin levels in subjects with nonalcoholic fatty liver disease.

[1]  T. Ueno,et al.  Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice. , 2009, Metabolism: clinical and experimental.

[2]  T. Ozgurtas,et al.  LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. , 2009, Atherosclerosis.

[3]  M. Nannipieri,et al.  Pattern of Expression of Adiponectin Receptors in Human Liver and its Relation to Nonalcoholic Steatohepatitis , 2009, Obesity surgery.

[4]  J. Kountouras,et al.  Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. , 2009, Current molecular medicine.

[5]  Raj Vuppalanchi,et al.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management , 2009, Hepatology.

[6]  W. Jiménez,et al.  The hepatic apelin system: A new therapeutic target for liver disease , 2008, Hepatology.

[7]  A. Sonmez,et al.  Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. , 2008, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[8]  P. Krieg,et al.  A putative role for apelin in the etiology of obesity. , 2008, Biochemical and biophysical research communications.

[9]  S. Kaneko,et al.  Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. , 2007, Metabolism: clinical and experimental.

[10]  M. Yılmaz,et al.  Plasma Apelin is Lower in Patients with Elevated LDL-Cholesterol , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[11]  J. Gómez-Reino,et al.  The emerging role of adipokines as mediators of inflammation and immune responses. , 2007, Cytokine & growth factor reviews.

[12]  R. Henry,et al.  Adiponectin in health and disease , 2007, Diabetes, obesity & metabolism.

[13]  T. Ozgurtas,et al.  Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. , 2007, Diabetes research and clinical practice.

[14]  I. Castan-Laurell,et al.  TNFα up‐regulates apelin expression in human and mouse adipose tissue , 2006 .

[15]  J. Bełtowski.  Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[16]  G. Marchesini,et al.  Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. , 2005, The Journal of clinical endocrinology and metabolism.

[17]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[18]  I. Castan-Laurell,et al.  Apelin, a newly identified adipokine up-regulated by insulin and obesity. , 2005, Endocrinology.

[19]  G. Targher,et al.  Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals , 2004, Clinical endocrinology.

[20]  J. Kench,et al.  Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.

[21]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[22]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[23]  L. Sechi,et al.  Plasma adiponectin is decreased in nonalcoholic fatty liver disease. , 2005, European journal of endocrinology.

[24]  E. Bonora,et al.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.